Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Study Purpose

This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 12 Months - 21 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621G based on the presence of a BRAF V600 mutation.
  • - Patients must have a body surface area >= 0.55 m^2 at enrollment; patients < 0.73 m^2 must follow the dosing nomogram; patients >= 0.73 m^2 at enrollment must follow the dosing nomogram.
  • - Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: - Malignant fluid collections (e.g., ascites, pleural effusions) - Bone marrow infiltration except that detected by MIBG scan for neuroblastoma.
  • - Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma.
  • - Elevated tumor markers in plasma or cerebrospinal fluid (CSF) - Previously radiated lesions that have not demonstrated clear progression post radiation.
  • - Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • - Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: Neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • - Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately.
  • - Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.
  • - >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea) - Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent.
  • - Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1.
  • - Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid.
  • - Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator.
  • - Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors) - Stem cell Infusions (with or without total-body irradiation [TBI]): - Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD) - Autologous stem cell infusion including boost infusion: >= 42 days.
  • - Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.) - Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation; Note: Radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment.
  • - Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131 [131I-MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy.
  • - Patients must not have received prior exposure to a BRAF inhibitor (e.g. vemurafenib, dabrafenib or encorafenib) - For patients with solid tumors without known bone marrow involvement: - Peripheral absolute neutrophil count (ANC) >= 1000/mm^3.
  • - Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) - Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts in above criteria (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity.
  • - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows: - Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6.
  • - Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8.
  • - Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1.
  • - Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2.
  • - Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4.
  • - Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4.
  • - Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age.
  • - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L) - Serum albumin >= 2 g/dL.
  • - Corrected QT (QTc) interval =< 480 milliseconds; Note: Patients should avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available.
  • - Patients must be able to swallow intact tablets.
  • - All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion Criteria:

  • - Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, for the duration of study treatment and for 6 months after the last dose of vemurafenib.
  • - Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid.
  • - Patients who are currently receiving another investigational drug are not eligible.
  • - Patients who are currently receiving other anti-cancer agents are not eligible.
  • - Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.
  • - Patients who are currently receiving drugs that are moderate to strong inducers or inhibitors of CYP3A4 are not eligible; moderate to strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed.
  • - Patients who are currently receiving drugs that are inhibitors or inducers of p-glycoprotein (P-gp) or adenosine triphosphate (ATP)-binding cassette, subfamily G, member 2 (ABCG2 [BCRP]) are not eligible.
  • - Patients with known active cutaneous squamous cell carcinoma (includes keratoacanthoma or mixed keratoacanthoma subtype) are not eligible; patients who have fully excised lesions with dermatologic confirmation of absence of disease are eligible.
  • - Patients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligible.
  • - Patients who have an uncontrolled infection are not eligible.
  • - Patients who have received a prior solid organ transplantation are not eligible.
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03220035
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

National Cancer Institute (NCI)
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

AeRang Kim
Principal Investigator Affiliation Children's Oncology Group
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

NIH
Overall Status Active, not recruiting
Countries Puerto Rico, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Additional Details

PRIMARY OBJECTIVE:

  • I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with vemurafenib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations.
SECONDARY OBJECTIVES:
  • I. To estimate the progression free survival in pediatric patients treated with vemurafenib with advanced solid tumors (including CNS tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations.
  • II. To obtain information about the tolerability of vemurafenib in children with relapsed or refractory cancer.
EXPLORATORY OBJECTIVE:
  • I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE: Patients receive vemurafenib orally (PO) twice daily (BID) on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Arms & Interventions

Arms

Experimental: Treatment (vemurafenib)

Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Interventions

Other: - Laboratory Biomarker Analysis

Correlative studies

Drug: - Vemurafenib

Given PO

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Children's Hospital of Alabama, Birmingham, Alabama

Status

Address

Children's Hospital of Alabama

Birmingham, Alabama, 35233

Providence Alaska Medical Center, Anchorage, Alaska

Status

Address

Providence Alaska Medical Center

Anchorage, Alaska, 99508

Banner Children's at Desert, Mesa, Arizona

Status

Address

Banner Children's at Desert

Mesa, Arizona, 85202

Tucson, Arizona

Status

Address

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Arkansas Children's Hospital, Little Rock, Arkansas

Status

Address

Arkansas Children's Hospital

Little Rock, Arkansas, 72202-3591

Kaiser Permanente Downey Medical Center, Downey, California

Status

Address

Kaiser Permanente Downey Medical Center

Downey, California, 90242

Loma Linda University Medical Center, Loma Linda, California

Status

Address

Loma Linda University Medical Center

Loma Linda, California, 92354

Long Beach, California

Status

Address

Miller Children's and Women's Hospital Long Beach

Long Beach, California, 90806

Children's Hospital Los Angeles, Los Angeles, California

Status

Address

Children's Hospital Los Angeles

Los Angeles, California, 90027

Valley Children's Hospital, Madera, California

Status

Address

Valley Children's Hospital

Madera, California, 93636

UCSF Benioff Children's Hospital Oakland, Oakland, California

Status

Address

UCSF Benioff Children's Hospital Oakland

Oakland, California, 94609

Kaiser Permanente-Oakland, Oakland, California

Status

Address

Kaiser Permanente-Oakland

Oakland, California, 94611

UCSF Medical Center-Mission Bay, San Francisco, California

Status

Address

UCSF Medical Center-Mission Bay

San Francisco, California, 94158

Children's Hospital Colorado, Aurora, Colorado

Status

Address

Children's Hospital Colorado

Aurora, Colorado, 80045

Denver, Colorado

Status

Address

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

Denver, Colorado, 80218

Yale University, New Haven, Connecticut

Status

Address

Yale University

New Haven, Connecticut, 06520

Alfred I duPont Hospital for Children, Wilmington, Delaware

Status

Address

Alfred I duPont Hospital for Children

Wilmington, Delaware, 19803

Children's National Medical Center, Washington, District of Columbia

Status

Address

Children's National Medical Center

Washington, District of Columbia, 20010

Broward Health Medical Center, Fort Lauderdale, Florida

Status

Address

Broward Health Medical Center

Fort Lauderdale, Florida, 33316

Gainesville, Florida

Status

Address

University of Florida Health Science Center - Gainesville

Gainesville, Florida, 32610

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Status

Address

Nemours Children's Clinic-Jacksonville

Jacksonville, Florida, 32207

Miami, Florida

Status

Address

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Nicklaus Children's Hospital, Miami, Florida

Status

Address

Nicklaus Children's Hospital

Miami, Florida, 33155

AdventHealth Orlando, Orlando, Florida

Status

Address

AdventHealth Orlando

Orlando, Florida, 32803

Arnold Palmer Hospital for Children, Orlando, Florida

Status

Address

Arnold Palmer Hospital for Children

Orlando, Florida, 32806

Nemours Children's Hospital, Orlando, Florida

Status

Address

Nemours Children's Hospital

Orlando, Florida, 32827

Nemours Children's Clinic - Pensacola, Pensacola, Florida

Status

Address

Nemours Children's Clinic - Pensacola

Pensacola, Florida, 32504

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Status

Address

Johns Hopkins All Children's Hospital

Saint Petersburg, Florida, 33701

Tampa, Florida

Status

Address

Saint Joseph's Hospital/Children's Hospital-Tampa

Tampa, Florida, 33607

Atlanta, Georgia

Status

Address

Children's Healthcare of Atlanta - Egleston

Atlanta, Georgia, 30322

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Status

Address

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Chicago, Illinois

Status

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Saint Jude Midwest Affiliate, Peoria, Illinois

Status

Address

Saint Jude Midwest Affiliate

Peoria, Illinois, 61637

Springfield, Illinois

Status

Address

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Riley Hospital for Children, Indianapolis, Indiana

Status

Address

Riley Hospital for Children

Indianapolis, Indiana, 46202

Blank Children's Hospital, Des Moines, Iowa

Status

Address

Blank Children's Hospital

Des Moines, Iowa, 50309

Iowa City, Iowa

Status

Address

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Lexington, Kentucky

Status

Address

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Norton Children's Hospital, Louisville, Kentucky

Status

Address

Norton Children's Hospital

Louisville, Kentucky, 40202

Children's Hospital New Orleans, New Orleans, Louisiana

Status

Address

Children's Hospital New Orleans

New Orleans, Louisiana, 70118

Ochsner Medical Center Jefferson, New Orleans, Louisiana

Status

Address

Ochsner Medical Center Jefferson

New Orleans, Louisiana, 70121

Eastern Maine Medical Center, Bangor, Maine

Status

Address

Eastern Maine Medical Center

Bangor, Maine, 04401

Sinai Hospital of Baltimore, Baltimore, Maryland

Status

Address

Sinai Hospital of Baltimore

Baltimore, Maryland, 21215

Baltimore, Maryland

Status

Address

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Boston, Massachusetts

Status

Address

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

Dana-Farber Cancer Institute, Boston, Massachusetts

Status

Address

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

C S Mott Children's Hospital, Ann Arbor, Michigan

Status

Address

C S Mott Children's Hospital

Ann Arbor, Michigan, 48109

Bronson Methodist Hospital, Kalamazoo, Michigan

Status

Address

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

Minneapolis, Minnesota

Status

Address

Children's Hospitals and Clinics of Minnesota - Minneapolis

Minneapolis, Minnesota, 55404

Minneapolis, Minnesota

Status

Address

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455

University of Mississippi Medical Center, Jackson, Mississippi

Status

Address

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Status

Address

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108

Saint Louis, Missouri

Status

Address

Cardinal Glennon Children's Medical Center

Saint Louis, Missouri, 63104

Washington University School of Medicine, Saint Louis, Missouri

Status

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Mercy Hospital Saint Louis, Saint Louis, Missouri

Status

Address

Mercy Hospital Saint Louis

Saint Louis, Missouri, 63141

Omaha, Nebraska

Status

Address

Children's Hospital and Medical Center of Omaha

Omaha, Nebraska, 68114

University of Nebraska Medical Center, Omaha, Nebraska

Status

Address

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Las Vegas, Nevada

Status

Address

University Medical Center of Southern Nevada

Las Vegas, Nevada, 89102

Las Vegas, Nevada

Status

Address

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas, Nevada, 89135

Summerlin Hospital Medical Center, Las Vegas, Nevada

Status

Address

Summerlin Hospital Medical Center

Las Vegas, Nevada, 89144

Hackensack University Medical Center, Hackensack, New Jersey

Status

Address

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Morristown Medical Center, Morristown, New Jersey

Status

Address

Morristown Medical Center

Morristown, New Jersey, 07960

Albany Medical Center, Albany, New York

Status

Address

Albany Medical Center

Albany, New York, 12208

Roswell Park Cancer Institute, Buffalo, New York

Status

Address

Roswell Park Cancer Institute

Buffalo, New York, 14263

New Hyde Park, New York

Status

Address

The Steven and Alexandra Cohen Children's Medical Center of New York

New Hyde Park, New York, 11040

New York, New York

Status

Address

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

NYP/Weill Cornell Medical Center, New York, New York

Status

Address

NYP/Weill Cornell Medical Center

New York, New York, 10065

University of Rochester, Rochester, New York

Status

Address

University of Rochester

Rochester, New York, 14642

Syracuse, New York

Status

Address

State University of New York Upstate Medical University

Syracuse, New York, 13210

New York Medical College, Valhalla, New York

Status

Address

New York Medical College

Valhalla, New York, 10595

Mission Hospital, Asheville, North Carolina

Status

Address

Mission Hospital

Asheville, North Carolina, 28801

Charlotte, North Carolina

Status

Address

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Charlotte, North Carolina

Status

Address

Novant Health Presbyterian Medical Center

Charlotte, North Carolina, 28204

Duke University Medical Center, Durham, North Carolina

Status

Address

Duke University Medical Center

Durham, North Carolina, 27710

Sanford Broadway Medical Center, Fargo, North Dakota

Status

Address

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Cincinnati, Ohio

Status

Address

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229

Cleveland Clinic Foundation, Cleveland, Ohio

Status

Address

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Nationwide Children's Hospital, Columbus, Ohio

Status

Address

Nationwide Children's Hospital

Columbus, Ohio, 43205

Dayton Children's Hospital, Dayton, Ohio

Status

Address

Dayton Children's Hospital

Dayton, Ohio, 45404

Toledo, Ohio

Status

Address

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, Ohio, 43606

Oklahoma City, Oklahoma

Status

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Legacy Emanuel Children's Hospital, Portland, Oregon

Status

Address

Legacy Emanuel Children's Hospital

Portland, Oregon, 97227

Oregon Health and Science University, Portland, Oregon

Status

Address

Oregon Health and Science University

Portland, Oregon, 97239

Geisinger Medical Center, Danville, Pennsylvania

Status

Address

Geisinger Medical Center

Danville, Pennsylvania, 17822

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Status

Address

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

Pittsburgh, Pennsylvania

Status

Address

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224

Prisma Health Richland Hospital, Columbia, South Carolina

Status

Address

Prisma Health Richland Hospital

Columbia, South Carolina, 29203

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Status

Address

BI-LO Charities Children's Cancer Center

Greenville, South Carolina, 29605

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

Status

Address

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

T C Thompson Children's Hospital, Chattanooga, Tennessee

Status

Address

T C Thompson Children's Hospital

Chattanooga, Tennessee, 37403

Saint Jude Children's Research Hospital, Memphis, Tennessee

Status

Address

Saint Jude Children's Research Hospital

Memphis, Tennessee, 38105

Nashville, Tennessee

Status

Address

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Austin, Texas

Status

Address

Dell Children's Medical Center of Central Texas

Austin, Texas, 78723

Medical City Dallas Hospital, Dallas, Texas

Status

Address

Medical City Dallas Hospital

Dallas, Texas, 75230

Dallas, Texas

Status

Address

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Cook Children's Medical Center, Fort Worth, Texas

Status

Address

Cook Children's Medical Center

Fort Worth, Texas, 76104

Houston, Texas

Status

Address

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

M D Anderson Cancer Center, Houston, Texas

Status

Address

M D Anderson Cancer Center

Houston, Texas, 77030

UMC Cancer Center / UMC Health System, Lubbock, Texas

Status

Address

UMC Cancer Center / UMC Health System

Lubbock, Texas, 79415

Children's Hospital of San Antonio, San Antonio, Texas

Status

Address

Children's Hospital of San Antonio

San Antonio, Texas, 78207

San Antonio, Texas

Status

Address

Methodist Children's Hospital of South Texas

San Antonio, Texas, 78229

San Antonio, Texas

Status

Address

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Scott and White Memorial Hospital, Temple, Texas

Status

Address

Scott and White Memorial Hospital

Temple, Texas, 76508

Primary Children's Hospital, Salt Lake City, Utah

Status

Address

Primary Children's Hospital

Salt Lake City, Utah, 84113

Burlington, Vermont

Status

Address

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Norfolk, Virginia

Status

Address

Children's Hospital of The King's Daughters

Norfolk, Virginia, 23507

Richmond, Virginia

Status

Address

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298

Seattle Children's Hospital, Seattle, Washington

Status

Address

Seattle Children's Hospital

Seattle, Washington, 98105

Spokane, Washington

Status

Address

Providence Sacred Heart Medical Center and Children's Hospital

Spokane, Washington, 99204

Madigan Army Medical Center, Tacoma, Washington

Status

Address

Madigan Army Medical Center

Tacoma, Washington, 98431

West Virginia University Healthcare, Morgantown, West Virginia

Status

Address

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Madison, Wisconsin

Status

Address

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Status

Address

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, 53226

International Sites

San Jorge Children's Hospital, San Juan, Puerto Rico

Status

Address

San Jorge Children's Hospital

San Juan, , 00912

University Pediatric Hospital, San Juan, Puerto Rico

Status

Address

University Pediatric Hospital

San Juan, , 00926

Stay Informed & Connected